LeMaitre Vascular/$LMAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LeMaitre Vascular
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Ticker
$LMAT
Sector
Primary listing
Employees
658
Headquarters
Website
LMAT Metrics
BasicAdvanced
$2.1B
45.02
$2.05
0.79
$0.76
0.87%
Price and volume
Market cap
$2.1B
Beta
0.79
52-week high
$107.03
52-week low
$71.42
Average daily volume
191K
Dividend rate
$0.76
Financial strength
Current ratio
13.958
Quick ratio
11.553
Long term debt to equity
50.473
Total debt to equity
51.253
Dividend payout ratio (TTM)
34.45%
Interest coverage (TTM)
19.60%
Profitability
EBITDA (TTM)
64.874
Gross margin (TTM)
69.11%
Net profit margin (TTM)
20.08%
Operating margin (TTM)
23.34%
Effective tax rate (TTM)
22.61%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
7.28%
Return on equity (TTM)
13.81%
Valuation
Price to earnings (TTM)
45.021
Price to revenue (TTM)
8.866
Price to book
5.76
Price to tangible book (TTM)
7.92
Price to free cash flow (TTM)
39.764
Free cash flow yield (TTM)
2.51%
Free cash flow per share (TTM)
2.321
Dividend yield (TTM)
0.82%
Forward dividend yield
0.87%
Growth
Revenue change (TTM)
14.11%
Earnings per share change (TTM)
22.69%
3-year revenue growth (CAGR)
13.72%
10-year revenue growth (CAGR)
12.18%
3-year earnings per share growth (CAGR)
26.92%
10-year earnings per share growth (CAGR)
20.17%
3-year dividend per share growth (CAGR)
15.28%
10-year dividend per share growth (CAGR)
16.98%
What the Analysts think about LMAT
Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
Bulls say / Bears say
LeMaitre posted Q2 2025 net sales of $64.23M, a 15% year-over-year increase, fueled by 27% growth in catheters and 19% growth in grafts—both beating analyst expectations.
The company improved its gross margin by 110 basis points to 70.0% in Q2 2025, highlighting strong pricing power—responsible for 8% of sales growth—and better manufacturing efficiency.
LeMaitre raised its full-year 2025 sales outlook to $248M–$254M and updated EPS guidance to $2.23–$2.37. It also maintained a $75M share buyback program and a $0.20 quarterly dividend, reflecting management’s confidence in strong cash flow.
Q3 2025 guidance indicates a sequential drop in sales to $61.2M–$63.2M (midpoint $62.2M, down from Q2’s $64.2M), suggesting weaker demand and possible seasonal risk.
LeMaitre’s stock trades at 37 times estimated earnings for the next twelve months, a premium valuation that could cap potential gains and increase downside risk if growth slows.
A warning letter from the FDA dated August 11, 2025 cites manufacturing violations for the Artegraft Collagen Vascular Graft under QSR 21 CFR Part 820, creating risks of regulatory penalties and supply chain disruptions.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
LMAT Financial Performance
Revenues and expenses
LMAT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LeMaitre Vascular stock?
LeMaitre Vascular (LMAT) has a market cap of $2.1B as of September 15, 2025.
What is the P/E ratio for LeMaitre Vascular stock?
The price to earnings (P/E) ratio for LeMaitre Vascular (LMAT) stock is 45.02 as of September 15, 2025.
Does LeMaitre Vascular stock pay dividends?
Yes, the LeMaitre Vascular (LMAT) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is $0.76 and the yield is 0.87%. LeMaitre Vascular has a payout ratio of 34.45% on a trailing twelve-month basis.
When is the next LeMaitre Vascular dividend payment date?
The next LeMaitre Vascular (LMAT) dividend payment date is unconfirmed.
What is the beta indicator for LeMaitre Vascular?
LeMaitre Vascular (LMAT) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.